Neither Gastric Bypass Surgery Nor Diet-Induced Weight-Loss Affect OATP1B1 Activity as Measured by Rosuvastatin Oral Clearance
ConclusionsNeither body weight, weight loss nor RYGB per se seem to affect OATP1B1 activity to a clinically relevant degree. Overall, the observed changes in rosuvastatin pharmacokinetics were minor, and unlikely to be of clinical relevance.
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
More News: Crestor | Diets | Drugs & Pharmacology | Eating Disorders & Weight Management | Gastric Bypass | Gastroenterology | Nutrition | Obesity | Rosuvastatin | Study | Weight Loss